Immunobiological properties of a recombinant simian retro virus-1 envelope protein and a neutralizing monoclonal antibody directed against it

Linda L. Werner, Jose V Torres, Cherry Y. Leung, Hwei Sing Kwang, Arthur Malley, Eli Benjamini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We previously reported that an area encompassing amino acids 147-162 of the envelope region of the simian (type D) retrovirus serotype 1 (SRV-1) constitutes an antigenic site for the binding of murine and rhesus neutralizing antibodies. Neutralizing antibodies to SRV-2 are directed to a different area, encompassing residues 96-102 of SRV-2. This paper presents data on the activity of an SRV-1 recombinant envelope protein (rEP) and of monoclonal hybridoma cell line, C11B8, produced from murine spleen cells immunized with SRV-1 rEP. Purified monoclonal antibodies from C11B8 bind to the SRV-1 rEP and to both SRV-1 and SRV-2. However, the monoclonal antibody exhibits strain specificity in the capacity to neutralize SRV-1 infection in vitro. Thus, C11B8 neutralizes SRV-1 infection but fails to neutralize four other known serotypes of the virus. C11B8 also binds to an SRV-1 synthetic peptide representing residues 142-167, which encompasses the previously defined antigenic site of recognition for neutralizing antibodies to SRV-1. This paper also contains evidence that the SRV-1 rEP construct binds the site for SRV-1 attachment to the cell receptor. This is indicated by the ability of SRV-1 rEP to compete with SRV-1 (but not with SRV-2) and inhibit its infectivity in vitro. In addition, SRV-1 rEP inhibits the neutralizing activity of C11B8 against SRV-1 infection in vitro. SRV-1 rEP has no inhibitory effect on rhesus neutralizing antibodies to SRV-2. Taken together, the above findings indicate that immunity conferred at the level of neutralizing antibodies during SRV infection is strain-specific and involves the recognition of envelope sequences unique to each strain.

Original languageEnglish (US)
Pages (from-to)819-826
Number of pages8
JournalMolecular Immunology
Volume28
Issue number8
DOIs
StatePublished - 1991

Fingerprint

Mason-Pfizer monkey virus
Viral Envelope Proteins
Neutralizing Antibodies
Monoclonal Antibodies
Recombinant Proteins
Infection
Simian Retroviruses

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Immunobiological properties of a recombinant simian retro virus-1 envelope protein and a neutralizing monoclonal antibody directed against it. / Werner, Linda L.; Torres, Jose V; Leung, Cherry Y.; Kwang, Hwei Sing; Malley, Arthur; Benjamini, Eli.

In: Molecular Immunology, Vol. 28, No. 8, 1991, p. 819-826.

Research output: Contribution to journalArticle

Werner, Linda L. ; Torres, Jose V ; Leung, Cherry Y. ; Kwang, Hwei Sing ; Malley, Arthur ; Benjamini, Eli. / Immunobiological properties of a recombinant simian retro virus-1 envelope protein and a neutralizing monoclonal antibody directed against it. In: Molecular Immunology. 1991 ; Vol. 28, No. 8. pp. 819-826.
@article{909710a660e6467d92d4be7402ccbfb6,
title = "Immunobiological properties of a recombinant simian retro virus-1 envelope protein and a neutralizing monoclonal antibody directed against it",
abstract = "We previously reported that an area encompassing amino acids 147-162 of the envelope region of the simian (type D) retrovirus serotype 1 (SRV-1) constitutes an antigenic site for the binding of murine and rhesus neutralizing antibodies. Neutralizing antibodies to SRV-2 are directed to a different area, encompassing residues 96-102 of SRV-2. This paper presents data on the activity of an SRV-1 recombinant envelope protein (rEP) and of monoclonal hybridoma cell line, C11B8, produced from murine spleen cells immunized with SRV-1 rEP. Purified monoclonal antibodies from C11B8 bind to the SRV-1 rEP and to both SRV-1 and SRV-2. However, the monoclonal antibody exhibits strain specificity in the capacity to neutralize SRV-1 infection in vitro. Thus, C11B8 neutralizes SRV-1 infection but fails to neutralize four other known serotypes of the virus. C11B8 also binds to an SRV-1 synthetic peptide representing residues 142-167, which encompasses the previously defined antigenic site of recognition for neutralizing antibodies to SRV-1. This paper also contains evidence that the SRV-1 rEP construct binds the site for SRV-1 attachment to the cell receptor. This is indicated by the ability of SRV-1 rEP to compete with SRV-1 (but not with SRV-2) and inhibit its infectivity in vitro. In addition, SRV-1 rEP inhibits the neutralizing activity of C11B8 against SRV-1 infection in vitro. SRV-1 rEP has no inhibitory effect on rhesus neutralizing antibodies to SRV-2. Taken together, the above findings indicate that immunity conferred at the level of neutralizing antibodies during SRV infection is strain-specific and involves the recognition of envelope sequences unique to each strain.",
author = "Werner, {Linda L.} and Torres, {Jose V} and Leung, {Cherry Y.} and Kwang, {Hwei Sing} and Arthur Malley and Eli Benjamini",
year = "1991",
doi = "10.1016/0161-5890(91)90045-L",
language = "English (US)",
volume = "28",
pages = "819--826",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Immunobiological properties of a recombinant simian retro virus-1 envelope protein and a neutralizing monoclonal antibody directed against it

AU - Werner, Linda L.

AU - Torres, Jose V

AU - Leung, Cherry Y.

AU - Kwang, Hwei Sing

AU - Malley, Arthur

AU - Benjamini, Eli

PY - 1991

Y1 - 1991

N2 - We previously reported that an area encompassing amino acids 147-162 of the envelope region of the simian (type D) retrovirus serotype 1 (SRV-1) constitutes an antigenic site for the binding of murine and rhesus neutralizing antibodies. Neutralizing antibodies to SRV-2 are directed to a different area, encompassing residues 96-102 of SRV-2. This paper presents data on the activity of an SRV-1 recombinant envelope protein (rEP) and of monoclonal hybridoma cell line, C11B8, produced from murine spleen cells immunized with SRV-1 rEP. Purified monoclonal antibodies from C11B8 bind to the SRV-1 rEP and to both SRV-1 and SRV-2. However, the monoclonal antibody exhibits strain specificity in the capacity to neutralize SRV-1 infection in vitro. Thus, C11B8 neutralizes SRV-1 infection but fails to neutralize four other known serotypes of the virus. C11B8 also binds to an SRV-1 synthetic peptide representing residues 142-167, which encompasses the previously defined antigenic site of recognition for neutralizing antibodies to SRV-1. This paper also contains evidence that the SRV-1 rEP construct binds the site for SRV-1 attachment to the cell receptor. This is indicated by the ability of SRV-1 rEP to compete with SRV-1 (but not with SRV-2) and inhibit its infectivity in vitro. In addition, SRV-1 rEP inhibits the neutralizing activity of C11B8 against SRV-1 infection in vitro. SRV-1 rEP has no inhibitory effect on rhesus neutralizing antibodies to SRV-2. Taken together, the above findings indicate that immunity conferred at the level of neutralizing antibodies during SRV infection is strain-specific and involves the recognition of envelope sequences unique to each strain.

AB - We previously reported that an area encompassing amino acids 147-162 of the envelope region of the simian (type D) retrovirus serotype 1 (SRV-1) constitutes an antigenic site for the binding of murine and rhesus neutralizing antibodies. Neutralizing antibodies to SRV-2 are directed to a different area, encompassing residues 96-102 of SRV-2. This paper presents data on the activity of an SRV-1 recombinant envelope protein (rEP) and of monoclonal hybridoma cell line, C11B8, produced from murine spleen cells immunized with SRV-1 rEP. Purified monoclonal antibodies from C11B8 bind to the SRV-1 rEP and to both SRV-1 and SRV-2. However, the monoclonal antibody exhibits strain specificity in the capacity to neutralize SRV-1 infection in vitro. Thus, C11B8 neutralizes SRV-1 infection but fails to neutralize four other known serotypes of the virus. C11B8 also binds to an SRV-1 synthetic peptide representing residues 142-167, which encompasses the previously defined antigenic site of recognition for neutralizing antibodies to SRV-1. This paper also contains evidence that the SRV-1 rEP construct binds the site for SRV-1 attachment to the cell receptor. This is indicated by the ability of SRV-1 rEP to compete with SRV-1 (but not with SRV-2) and inhibit its infectivity in vitro. In addition, SRV-1 rEP inhibits the neutralizing activity of C11B8 against SRV-1 infection in vitro. SRV-1 rEP has no inhibitory effect on rhesus neutralizing antibodies to SRV-2. Taken together, the above findings indicate that immunity conferred at the level of neutralizing antibodies during SRV infection is strain-specific and involves the recognition of envelope sequences unique to each strain.

UR - http://www.scopus.com/inward/record.url?scp=0025772664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025772664&partnerID=8YFLogxK

U2 - 10.1016/0161-5890(91)90045-L

DO - 10.1016/0161-5890(91)90045-L

M3 - Article

C2 - 1715026

AN - SCOPUS:0025772664

VL - 28

SP - 819

EP - 826

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 8

ER -